CRVS CORVUS PHARMACEUTICALS INC
FollowCOM (common), issuer CIK 1626971
Filings received so far for Q3 2026: 6 13F filers report a position in CRVS shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.
Insider trades
No Form 4 transaction on this security in the data.
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
| Holder | Shares | Value | % of portfolio | Change | Source |
|---|---|---|---|---|---|
| Hennion & Walsh Asset Management, Inc. | 52,673 | $607K | 0.02% | new | 13F-HRTimeline |
| AVITY INVESTMENT MANAGEMENT INC. | 34,800 | $401K | 0.03% | -2,350 | 13F-HRTimeline |
| GAMMA Investing LLC | 1,149 | $13.2K | <0.01% | +470 | 13F-HRTimeline |
| EASTERN BANK | 92 | $1.06K | <0.01% | 0 | 13F-HRTimeline |
| Farther Finance Advisors, LLC | 39 | $449 | <0.01% | -387 | 13F-HRTimeline |
| Versant Capital Management, Inc | 28 | $323 | <0.01% | 0 | 13F-HRTimeline |